Gosset Ownership
Private
Employees
~27
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Reverie Labs General Information
Reverie Labs developed advanced machine learning platforms that accelerate preclinical drug development by optimizing lead generation with a focus on kinase inhibitors. As of May 2023, they had four candidates in various stages from early discovery through IND-enabling. Their technology integrates multi-objective optimization balancing potency with pharmacokinetic properties. Post-acquisition by Ginkgo Bioworks, their platform is being integrated into broader AI-driven biology engineering efforts.
Contact Information
Primary Industry
Biotech
Corporate Office
Cambridge, Massachusetts
USA
USA
Drug Pipeline
No pipeline data available
Key Partnerships
Prior collaborations included partnerships with Roche / GNE; now part of Ginkgo’s broader biopharma customer ecosystem.
Reverie Labs Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Feb 10, 2021 | $25.0M | Completed | Preclinical |
To view Reverie Labs's complete valuation and funding history, request access »